View in EDS

Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.

Saved in:
Bibliographic Details
Title: Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
Authors: Mok, Tony S.1, Cheng, Ying2, Zhou, Xiangdong3, Lee, Ki Hyeong4, Nakagawa, Kazuhiko5, Niho, Seiji6, Chawla, Alka7, Rosell, Rafael8, Corral, Jesus9, Migliorino, Maria Rita10, Pluzanski, Adam11, Noonan, Kay12, Tang, Yiyun13, Pastel, Malaika14, Wilner, Keith D.13, Wu, Yi-Long15 syylwu@live.cn
Source: Drugs. Feb2021, Vol. 81 Issue 2, p257-266.
Database: SPORTDiscus with Full Text
Description
ISSN:00126667
DOI:10.1007/s40265-020-01441-6